계정 가입
email 로 로그인
email 로 가입
수신함을 확인하세요
BIND Therapeutics
About
BIND Therapeutics is a clinical-stage nanomedicine platform company developing Accurins, a class of highly selective, targeted therapeutics.
- 51 - 100
Details
- Last Funding Type
- Series C
- Last Funding Money Raised
- $12.40M
- Industries
- Biotechnology,Clinical Trials,Health Care,Information Technology,Medical
- Founded date
- Jan 1, 2006
- Number Of Employee
- 51 - 100
- Operating Status
- Active
They are a clinical-stage nanomedicine platform company developing Accurins™, our novel targeted and programmable therapeutics. Accurins are designed with specified physical and chemical characteristics to target specific cells or tissues and concentrate a therapeutic payload at the site of disease to enhance efficacy while minimizing adverse effects on healthy tissues. Our strategy is to leverage our medicinal nanoengineering platform to develop our own pipeline of Accurins, initially in oncology, as well as Accurins in collaboration with biopharmaceutical companies. Our lead drug candidate, BIND-014, is in Phase 2 clinical trials for non-small cell lung cancer (NSCLC) and metastatic castrate-resistant prostate cancer (mCRPC). To date in 2013, we have announced collaborations with Amgen, Pfizer and AstraZeneca to develop Accurins based on therapeutic payloads from their product pipelines.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Jun 29, 2010 | Series C | $12.40M | 1 | — | — | Detail |
| Nov 27, 2007 | Series B | $16M | 1 | — | — | Detail |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
ARCH Venture Partners
|
— | Series C |
